Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?,American Journal of Hematology

当前位置： X-MOL 学术 › Am. J. Hematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
American Journal of Hematology ( IF 10.1 ) Pub Date : 2024-07-17 , DOI: 10.1002/ajh.27434
Jennifer Marvin-Peek ₁ , Jason S Gilbert ₂ , Daniel A Pollyea ₃ , Courtney D DiNardo ₁

Affiliation

The advent of molecularly targeted therapeutics has transformed the management of patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive chemotherapy, lower intensity therapies (LIT) incorporating small molecules have significantly improved patient outcomes. With BCL2, IDH1, IDH2, and FLT3 inhibitors widely used for relapsed AML, combination regimens are now utilized in the frontline. Expansion of these targeted LIT combinations, along with development of novel agents including menin inhibitors, exemplifies the promise of precision medicine. Further understanding of molecular drivers of leukemic transformation and mechanisms of relapse will continue to advance frontline treatment options for patients with AML.

中文翻译：

较低强度治疗方案的急性髓系白血病一线治疗：我们现在在哪里以及我们可以去哪里？

分子靶向治疗的出现改变了急性髓系白血病 (AML) 患者的治疗方法。特别是对于不适合强化化疗的个体，结合小分子的低强度疗法（LIT）可以显着改善患者的治疗效果。随着 BCL2、IDH1、IDH2 和 FLT3 抑制剂广泛用于治疗复发性 AML，联合治疗方案现在已用于一线治疗。这些靶向 LIT 组合的扩展，以及包括 menin 抑制剂在内的新型药物的开发，体现了精准医疗的前景。对白血病转化的分子驱动因素和复发机制的进一步了解将继续推进 AML 患者的一线治疗选择。

更新日期：2024-07-17

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南